Medical technology company SciBase Holding AB (STO:SCIB) announced on Wednesday a strategic collaboration with Italian firm Kilabs srl to enhance skin cancer diagnostics in Italy.

Kilabs, recognized for its expertise in dermatology, will introduce SciBase's Nevisense technology, tailored for the Italian market, with an expected launch in the first half of 2025. To facilitate a smooth rollout, Kilabs will begin market preparations immediately.

Italy faces a rising incidence of skin cancer, with mortality rates increasing, especially among men. Nevisense offers a non-invasive, advanced approach to early melanoma detection, aiming to improve patient outcomes significantly.

CEO Michelangelo Simonelli, supported by experts Alessandro Cappella and Giuseppe Romano, is leading Kilabs' integration of Nevisense into clinical practice. This collaboration reflects Kilabs' dedication to healthcare innovation and enhanced standards in Italian dermatology.